Skip to main content
NCBI home page
Journal of Psychiatry & Neuroscience : JPN logoLink to Journal of Psychiatry & Neuroscience : JPN
. 1999 Nov;24(5):431–441.

Conventional versus novel antipsychotics: changing concepts and clinical implications.

G Remington 1, S A Chong 1
PMCID: PMC1189057  PMID: 10586534

Abstract

Novel antipsychotics represent a significant advance in the treatment of schizophrenia after many years of few developments. The conventional antipsychotics are potent D2 antagonists, but fail to achieve a response in about 30% of cases. They are also associated with a high rate of extrapyramidal side effects. The greater and broader spectrum of efficacy combined with the reduced short- and long-term side effects of the new drugs such as quetiapine, risperidone, olanzapine and ziprasidone, contribute to a fresh optimism for the pharmacotherapy of schizophrenia. These novel agents are now driving further advances in schizophrenia research through a growing understanding of their pharmacological and clinical profiles. Clozapine, the first novel antipsychotic, has relatively low activity at D2 receptors, a high affinity for D4 receptors and a greater 5-HT2 (serotonin) than D2 antagonism. Hence, clozapine and other novel antipsychotics can be classified as such by this latter characteristic. However, some of these drugs have D2 occupancy greater than 60% (the clinical response threshold), while others have a lower D2 occupancy. The novel antipsychotics according have also been classified according to their activity on different neurotransmitter systems. While more effective, novel antipsychotics are not a panacea; they have limitations and side effects. In clinical practice, the American Psychiatric Association recommends either a conventional or novel antipsychotic for initial treatment of schizophrenia, whereas Canadian guidelines recommend novel agents. These agents should also be considered for treatment of refractory schizophrenia. Patients whose schizophrenia does not respond to one of these agents may respond to another. Future research should involve longer clinical trials, given the long periods needed to establish efficacy, and should address many remaining questions about the novel agents.

Full text

PDF
431

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arvanitis L. A., Miller B. G. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry. 1997 Aug 15;42(4):233–246. doi: 10.1016/s0006-3223(97)00190-x. [DOI] [PubMed] [Google Scholar]
  2. Avnon M., Kunin A. Risperidone response after no clozapine response. Br J Psychiatry. 1995 Nov;167(5):699–699. doi: 10.1192/bjp.167.5.699. [DOI] [PubMed] [Google Scholar]
  3. Awad A. G. Subjective response to neuroleptics in schizophrenia. Schizophr Bull. 1993;19(3):609–618. doi: 10.1093/schbul/19.3.609. [DOI] [PubMed] [Google Scholar]
  4. Baldessarini R. J., Cohen B. M., Teicher M. H. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry. 1988 Jan;45(1):79–91. doi: 10.1001/archpsyc.1988.01800250095013. [DOI] [PubMed] [Google Scholar]
  5. Baldessarini R. J., Katz B., Cotton P. Dissimilar dosing with high-potency and low-potency neuroleptics. Am J Psychiatry. 1984 Jun;141(6):748–752. doi: 10.1176/ajp.141.6.748. [DOI] [PubMed] [Google Scholar]
  6. Beasley C. M., Jr, Tollefson G., Tran P., Satterlee W., Sanger T., Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 1996 Feb;14(2):111–123. doi: 10.1016/0893-133X(95)00069-P. [DOI] [PubMed] [Google Scholar]
  7. Bollini P., Pampallona S., Orza M. J., Adams M. E., Chalmers T. C. Antipsychotic drugs: is more worse? A meta-analysis of the published randomized control trials. Psychol Med. 1994 May;24(2):307–316. doi: 10.1017/s003329170002729x. [DOI] [PubMed] [Google Scholar]
  8. Bondolfi G., Dufour H., Patris M., May J. P., Billeter U., Eap C. B., Baumann P. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. Am J Psychiatry. 1998 Apr;155(4):499–504. doi: 10.1176/ajp.155.4.499. [DOI] [PubMed] [Google Scholar]
  9. Borison R. L., Pathiraja A. P., Diamond B. I., Meibach R. C. Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacol Bull. 1992;28(2):213–218. [PubMed] [Google Scholar]
  10. Breier A., Buchanan R. W., Kirkpatrick B., Davis O. R., Irish D., Summerfelt A., Carpenter W. T., Jr Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry. 1994 Jan;151(1):20–26. doi: 10.1176/ajp.151.1.20. [DOI] [PubMed] [Google Scholar]
  11. Brenner H. D., Dencker S. J., Goldstein M. J., Hubbard J. W., Keegan D. L., Kruger G., Kulhanek F., Liberman R. P., Malm U., Midha K. K. Defining treatment refractoriness in schizophrenia. Schizophr Bull. 1990;16(4):551–561. doi: 10.1093/schbul/16.4.551. [DOI] [PubMed] [Google Scholar]
  12. CARLSSON A., LINDQVIST M. EFFECT OF CHLORPROMAZINE OR HALOPERIDOL ON FORMATION OF 3METHOXYTYRAMINE AND NORMETANEPHRINE IN MOUSE BRAIN. Acta Pharmacol Toxicol (Copenh) 1963;20:140–144. doi: 10.1111/j.1600-0773.1963.tb01730.x. [DOI] [PubMed] [Google Scholar]
  13. Carpenter W. T., Jr, Heinrichs D. W., Wagman A. M. Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry. 1988 May;145(5):578–583. doi: 10.1176/ajp.145.5.578. [DOI] [PubMed] [Google Scholar]
  14. Casey D. E. Extrapyramidal syndromes in nonhuman primates: typical and atypical neuroleptics. Psychopharmacol Bull. 1991;27(1):47–50. [PubMed] [Google Scholar]
  15. Casey D. E., Keepers G. A. Neuroleptic side effects: acute extrapyramidal syndromes and tardive dyskinesia. Psychopharmacol Ser. 1988;5:74–93. doi: 10.1007/978-3-642-73280-5_7. [DOI] [PubMed] [Google Scholar]
  16. Chakos M. H., Lieberman J. A., Alvir J., Bilder R., Ashtari M. Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine. Lancet. 1995 Feb 18;345(8947):456–457. doi: 10.1016/s0140-6736(95)90441-7. [DOI] [PubMed] [Google Scholar]
  17. Chouinard G., Annable L., Ross-Chouinard A., Mercier P. A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases. J Clin Psychopharmacol. 1988 Aug;8(4 Suppl):21S–26S. [PubMed] [Google Scholar]
  18. Chouinard G., Jones B., Remington G., Bloom D., Addington D., MacEwan G. W., Labelle A., Beauclair L., Arnott W. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol. 1993 Feb;13(1):25–40. [PubMed] [Google Scholar]
  19. Christison G. W., Kirch D. G., Wyatt R. J. When symptoms persist: choosing among alternative somatic treatments for schizophrenia. Schizophr Bull. 1991;17(2):217–245. doi: 10.1093/schbul/17.2.217. [DOI] [PubMed] [Google Scholar]
  20. Claus A., Bollen J., De Cuyper H., Eneman M., Malfroid M., Peuskens J., Heylen S. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand. 1992 Apr;85(4):295–305. doi: 10.1111/j.1600-0447.1992.tb01473.x. [DOI] [PubMed] [Google Scholar]
  21. Conley R. R., Schulz S. C., Baker R. W., Collins J. F., Bell J. A. Clozapine efficacy in schizophrenic nonresponders. Psychopharmacol Bull. 1988;24(2):269–274. [PubMed] [Google Scholar]
  22. Daniel D. G., Goldberg T. E., Weinberger D. R., Kleinman J. E., Pickar D., Lubick L. J., Williams T. S. Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study. Am J Psychiatry. 1996 Mar;153(3):417–419. doi: 10.1176/ajp.153.3.417. [DOI] [PubMed] [Google Scholar]
  23. Farde L., Nordström A. L., Wiesel F. A., Pauli S., Halldin C., Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry. 1992 Jul;49(7):538–544. doi: 10.1001/archpsyc.1992.01820070032005. [DOI] [PubMed] [Google Scholar]
  24. Fink M., Sackeim H. A. Convulsive therapy in schizophrenia? Schizophr Bull. 1996;22(1):27–39. doi: 10.1093/schbul/22.1.27. [DOI] [PubMed] [Google Scholar]
  25. Fogelson D. L., Sternbach H., Payne D. A naturalistic pilot study comparing haloperidol, clozapine, sertindole, and risperidone in partially responsive chronic schizophrenia or schizoaffective disorder. J Clin Psychopharmacol. 1997 Dec;17(6):492–494. doi: 10.1097/00004714-199712000-00013. [DOI] [PubMed] [Google Scholar]
  26. Fujii D. E., Ahmed I., Jokumsen M., Compton J. M. The effects of clozapine on cognitive functioning in treatment-resistant schizophrenic patients. J Neuropsychiatry Clin Neurosci. 1997 Spring;9(2):240–245. doi: 10.1176/jnp.9.2.240. [DOI] [PubMed] [Google Scholar]
  27. Gerlach J., Peacock L. Motor and mental side effects of clozapine. J Clin Psychiatry. 1994 Sep;55 (Suppl B):107–109. [PubMed] [Google Scholar]
  28. Gerlach J., Peacock L. New antipsychotics: the present status. Int Clin Psychopharmacol. 1995 Sep;10 (Suppl 3):39–48. doi: 10.1097/00004850-199509000-00006. [DOI] [PubMed] [Google Scholar]
  29. Glazer W. M., Kane J. M. Depot neuroleptic therapy: an underutilized treatment option. J Clin Psychiatry. 1992 Dec;53(12):426–433. [PubMed] [Google Scholar]
  30. Hagger C., Buckley P., Kenny J. T., Friedman L., Ubogy D., Meltzer H. Y. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry. 1993 Nov 15;34(10):702–712. doi: 10.1016/0006-3223(93)90043-d. [DOI] [PubMed] [Google Scholar]
  31. Herrera J. M., Costa J., Sramek J., Heh C. Clozapine in refractory schizophrenia. Preliminary findings. Schizophr Res. 1988 Jul-Aug;1(4):305–306. doi: 10.1016/0920-9964(88)90008-4. [DOI] [PubMed] [Google Scholar]
  32. Hoff A. L., Faustman W. O., Wieneke M., Espinoza S., Costa M., Wolkowitz O., Csernansky J. G. The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients. Neuropsychopharmacology. 1996 Oct;15(4):361–369. doi: 10.1016/0893-133X(95)00242-6. [DOI] [PubMed] [Google Scholar]
  33. Holland D., Watanabe M. D., Sharma R. Atypical antipsychotics. Psychiatr Med. 1991;9(1):5–24. [PubMed] [Google Scholar]
  34. Honigfeld G., Patin J. A two-year clinical and economic follow-up of patients on clozapine. Hosp Community Psychiatry. 1990 Aug;41(8):882–885. doi: 10.1176/ps.41.8.882. [DOI] [PubMed] [Google Scholar]
  35. Huttunen M. O., Piepponen T., Rantanen H., Larmo I., Nyholm R., Raitasuo V. Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel-group trial. Acta Psychiatr Scand. 1995 Apr;91(4):271–277. doi: 10.1111/j.1600-0447.1995.tb09781.x. [DOI] [PubMed] [Google Scholar]
  36. Høyberg O. J., Fensbo C., Remvig J., Lingjaerde O., Sloth-Nielsen M., Salvesen I. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr Scand. 1993 Dec;88(6):395–402. doi: 10.1111/j.1600-0447.1993.tb03480.x. [DOI] [PubMed] [Google Scholar]
  37. Jonsson D., Wålinder J. Cost-effectiveness of clozapine treatment in therapy-refractory schizophrenia. Acta Psychiatr Scand. 1995 Sep;92(3):199–201. doi: 10.1111/j.1600-0447.1995.tb09568.x. [DOI] [PubMed] [Google Scholar]
  38. Juul Povlsen U., Noring U., Fog R., Gerlach J. Tolerability and therapeutic effect of clozapine. A retrospective investigation of 216 patients treated with clozapine for up to 12 years. Acta Psychiatr Scand. 1985 Feb;71(2):176–185. doi: 10.1111/j.1600-0447.1985.tb01268.x. [DOI] [PubMed] [Google Scholar]
  39. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988 Sep;45(9):789–796. doi: 10.1001/archpsyc.1988.01800330013001. [DOI] [PubMed] [Google Scholar]
  40. Kapur S. A new framework for investigating antipsychotic action in humans: lessons from PET imaging. Mol Psychiatry. 1998 Mar;3(2):135–140. doi: 10.1038/sj.mp.4000327. [DOI] [PubMed] [Google Scholar]
  41. Kapur S., Remington G., Jones C., Wilson A., DaSilva J., Houle S., Zipursky R. High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study. Am J Psychiatry. 1996 Jul;153(7):948–950. doi: 10.1176/ajp.153.7.948. [DOI] [PubMed] [Google Scholar]
  42. Kapur S., Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry. 1996 Apr;153(4):466–476. doi: 10.1176/ajp.153.4.466. [DOI] [PubMed] [Google Scholar]
  43. Kapur S., Zipursky R. B., Remington G., Jones C., DaSilva J., Wilson A. A., Houle S. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry. 1998 Jul;155(7):921–928. doi: 10.1176/ajp.155.7.921. [DOI] [PubMed] [Google Scholar]
  44. Kapur S., Zipursky R., Remington G., Jones C., McKay G., Houle S. PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: implications for the therapeutics of schizophrenia. Am J Psychiatry. 1997 Nov;154(11):1525–1529. doi: 10.1176/ajp.154.11.1525. [DOI] [PubMed] [Google Scholar]
  45. Karasu C., Soncul H., Altan V. M. Effects of non-insulin dependent diabetes mellitus on the reactivity of human internal mammary artery and human saphenous vein. Life Sci. 1995;57(2):103–112. doi: 10.1016/0024-3205(95)00251-z. [DOI] [PubMed] [Google Scholar]
  46. Kerwin R. W. The new atypical antipsychotics. A lack of extrapyramidal side-effects and new routes in schizophrenia research. Br J Psychiatry. 1994 Feb;164(2):141–148. doi: 10.1192/bjp.164.2.141. [DOI] [PubMed] [Google Scholar]
  47. Keshavan M. S., Bagwell W. W., Haas G. L., Sweeney J. A., Schooler N. R., Pettegrew J. W. Changes in caudate volume with neuroleptic treatment. Lancet. 1994 Nov 19;344(8934):1434–1434. doi: 10.1016/s0140-6736(94)90599-1. [DOI] [PubMed] [Google Scholar]
  48. Kramer M. S., Last B., Getson A., Reines S. A. The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group. Arch Gen Psychiatry. 1997 Jun;54(6):567–572. doi: 10.1001/archpsyc.1997.01830180085011. [DOI] [PubMed] [Google Scholar]
  49. Kumra S., Frazier J. A., Jacobsen L. K., McKenna K., Gordon C. T., Lenane M. C., Hamburger S. D., Smith A. K., Albus K. E., Alaghband-Rad J. Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry. 1996 Dec;53(12):1090–1097. doi: 10.1001/archpsyc.1996.01830120020005. [DOI] [PubMed] [Google Scholar]
  50. Lacey R. L., Preskorn S. H., Jerkovich G. S. Is risperidone a substitute for clozapine for patients who do not respond to neuroleptics? Am J Psychiatry. 1995 Sep;152(9):1401–1401. doi: 10.1176/ajp.152.9.1401a. [DOI] [PubMed] [Google Scholar]
  51. Lieberman J. A. Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis. J Clin Psychiatry. 1996;57 (Suppl 11):68–71. [PubMed] [Google Scholar]
  52. Lieberman J. A. Understanding the mechanism of action of atypical antipsychotic drugs. A review of compounds in use and development. Br J Psychiatry Suppl. 1993 Dec;(22):7–18. [PubMed] [Google Scholar]
  53. Loebel A. D., Lieberman J. A., Alvir J. M., Mayerhoff D. I., Geisler S. H., Szymanski S. R. Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry. 1992 Sep;149(9):1183–1188. doi: 10.1176/ajp.149.9.1183. [DOI] [PubMed] [Google Scholar]
  54. Marder S. R., Meibach R. C. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994 Jun;151(6):825–835. doi: 10.1176/ajp.151.6.825. [DOI] [PubMed] [Google Scholar]
  55. McEvoy J. P., Hogarty G. E., Steingard S. Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry. 1991 Aug;48(8):739–745. doi: 10.1001/archpsyc.1991.01810320063009. [DOI] [PubMed] [Google Scholar]
  56. Meltzer H. Y., Cola P., Way L., Thompson P. A., Bastani B., Davies M. A., Snitz B. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry. 1993 Nov;150(11):1630–1638. doi: 10.1176/ajp.150.11.1630. [DOI] [PubMed] [Google Scholar]
  57. Meltzer H. Y. Duration of a clozapine trial in neuroleptic-resistant schizophrenia. Arch Gen Psychiatry. 1989 Jul;46(7):672–672. doi: 10.1001/archpsyc.1989.01810070098017. [DOI] [PubMed] [Google Scholar]
  58. Meltzer H. Y., Matsubara S., Lee J. C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther. 1989 Oct;251(1):238–246. [PubMed] [Google Scholar]
  59. Meltzer H. Y., Matsubara S., Lee J. C. The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull. 1989;25(3):390–392. [PubMed] [Google Scholar]
  60. Meltzer H. Y. Treatment of the neuroleptic-nonresponsive schizophrenic patient. Schizophr Bull. 1992;18(3):515–542. doi: 10.1093/schbul/18.3.515. [DOI] [PubMed] [Google Scholar]
  61. Mok H., Yatham L. N. Response to clozapine as a predictor of risperidone response in schizophrenia. Am J Psychiatry. 1994 Sep;151(9):1393–1394. doi: 10.1176/ajp.151.9.1393a. [DOI] [PubMed] [Google Scholar]
  62. Naber D., Hippius H. The European experience with use of clozapine. Hosp Community Psychiatry. 1990 Aug;41(8):886–890. doi: 10.1176/ps.41.8.886. [DOI] [PubMed] [Google Scholar]
  63. Nordström A. L., Farde L., Nyberg S., Karlsson P., Halldin C., Sedvall G. D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry. 1995 Oct;152(10):1444–1449. doi: 10.1176/ajp.152.10.1444. [DOI] [PubMed] [Google Scholar]
  64. Nordström A. L., Farde L., Wiesel F. A., Forslund K., Pauli S., Halldin C., Uppfeldt G. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry. 1993 Feb 15;33(4):227–235. doi: 10.1016/0006-3223(93)90288-o. [DOI] [PubMed] [Google Scholar]
  65. O'Hara P., Brugha T. S., Lesage A., Wing J. New findings on tardive dyskinesia in a community sample. Psychol Med. 1993 May;23(2):453–465. doi: 10.1017/s0033291700028543. [DOI] [PubMed] [Google Scholar]
  66. Peacock L., Solgaard T., Lublin H., Gerlach J. Clozapine versus typical antipsychotics. A retro- and prospective study of extrapyramidal side effects. Psychopharmacology (Berl) 1996 Mar;124(1-2):188–196. doi: 10.1007/BF02245620. [DOI] [PubMed] [Google Scholar]
  67. Perkins D. O., Lieberman J. A. Medical complications and selectivity of therapeutic response to atypical antipsychotic drugs. Am J Psychiatry. 1998 Feb;155(2):272–276. doi: 10.1176/ajp.155.2.272. [DOI] [PubMed] [Google Scholar]
  68. Peuskens J., Link C. G. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand. 1997 Oct;96(4):265–273. doi: 10.1111/j.1600-0447.1997.tb10162.x. [DOI] [PubMed] [Google Scholar]
  69. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry. 1995 Jun;166(6):712–733. doi: 10.1192/bjp.166.6.712. [DOI] [PubMed] [Google Scholar]
  70. Revicki D. A., Luce B. R., Weschler J. M., Brown R. E., Adler M. A. Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients. Hosp Community Psychiatry. 1990 Aug;41(8):850–854. doi: 10.1176/ps.41.8.850. [DOI] [PubMed] [Google Scholar]
  71. Rosenheck R., Cramer J., Xu W., Thomas J., Henderson W., Frisman L., Fye C., Charney D. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. N Engl J Med. 1997 Sep 18;337(12):809–815. doi: 10.1056/NEJM199709183371202. [DOI] [PubMed] [Google Scholar]
  72. Schmauss C., Emrich H. M. Dopamine and the action of opiates: a reevaluation of the dopamine hypothesis of schizophrenia. With special consideration of the role of endogenous opioids in the pathogenesis of schizophrenia. Biol Psychiatry. 1985 Nov;20(11):1211–1231. doi: 10.1016/0006-3223(85)90179-9. [DOI] [PubMed] [Google Scholar]
  73. Scully P. J., Coakley G., Kinsella A., Waddington J. L. Psychopathology, executive (frontal) and general cognitive impairment in relation to duration of initially untreated versus subsequently treated psychosis in chronic schizophrenia. Psychol Med. 1997 Nov;27(6):1303–1310. doi: 10.1017/s0033291797005722. [DOI] [PubMed] [Google Scholar]
  74. Seeman P. Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacology. 1992 Dec;7(4):261–284. [PubMed] [Google Scholar]
  75. Smith R. C., Chua J. W., Lipetsker B., Bhattacharyya A. Efficacy of risperidone in reducing positive and negative symptoms in medication-refractory schizophrenia: an open prospective study. J Clin Psychiatry. 1996 Oct;57(10):460–466. doi: 10.4088/jcp.v57n1004. [DOI] [PubMed] [Google Scholar]
  76. Still D. J., Dorson P. G., Crismon M. L., Pousson C. Effects of switching inpatients with treatment-resistant schizophrenia from clozapine to risperidone. Psychiatr Serv. 1996 Dec;47(12):1382–1384. doi: 10.1176/ps.47.12.1382. [DOI] [PubMed] [Google Scholar]
  77. Stone C. K., Garve D. L., Griffith J., Hirschowitz J., Bennett J. Further evidence of a dose-response threshold for haloperidol in psychosis. Am J Psychiatry. 1995 Aug;152(8):1210–1212. doi: 10.1176/ajp.152.8.1210. [DOI] [PubMed] [Google Scholar]
  78. Tollefson G. D., Beasley C. M., Jr, Tran P. V., Street J. S., Krueger J. A., Tamura R. N., Graffeo K. A., Thieme M. E. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry. 1997 Apr;154(4):457–465. doi: 10.1176/ajp.154.4.457. [DOI] [PubMed] [Google Scholar]
  79. Tran P. V., Hamilton S. H., Kuntz A. J., Potvin J. H., Andersen S. W., Beasley C., Jr, Tollefson G. D. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol. 1997 Oct;17(5):407–418. doi: 10.1097/00004714-199710000-00010. [DOI] [PubMed] [Google Scholar]
  80. Waddington J. L., Scully P. J., O'Callaghan E. The new antipsychotics, and their potential for early intervention in schizophrenia. Schizophr Res. 1997 Dec 19;28(2-3):207–222. doi: 10.1016/s0920-9964(97)00115-1. [DOI] [PubMed] [Google Scholar]
  81. Weiden P. J., Olfson M. Cost of relapse in schizophrenia. Schizophr Bull. 1995;21(3):419–429. doi: 10.1093/schbul/21.3.419. [DOI] [PubMed] [Google Scholar]
  82. Weiden P., Aquila R., Standard J. Atypical antipsychotic drugs and long-term outcome in schizophrenia. J Clin Psychiatry. 1996;57 (Suppl 11):53–60. [PubMed] [Google Scholar]
  83. Wilson W. H. Time required for initial improvement during clozapine treatment of refractory schizophrenia. Am J Psychiatry. 1996 Jul;153(7):951–952. doi: 10.1176/ajp.153.7.951. [DOI] [PubMed] [Google Scholar]
  84. Wyatt R. J. Early intervention for schizophrenia: can the course of the illness be altered? Biol Psychiatry. 1995 Jul 1;38(1):1–3. doi: 10.1016/0006-3223(95)00191-I. [DOI] [PubMed] [Google Scholar]
  85. Wyatt R. J. Neuroleptics and the natural course of schizophrenia. Schizophr Bull. 1991;17(2):325–351. doi: 10.1093/schbul/17.2.325. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Psychiatry and Neuroscience are provided here courtesy of Canadian Medical Association

RESOURCES